Avid Bioservices, Inc. reiterated revenue guidance for full fiscal year 2024. For the period, the company expects revenue to be between $145 million and $165 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.03 USD | -3.02% | +1.01% | +23.54% |
04-30 | RBC Lifts Price Target on Avid Bioservices to $8 From $7, Keeps Outperform Rating | MT |
04-29 | Transcript : Avid Bioservices, Inc., Q3 2024 Earnings Call, Apr 29, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.54% | 510M | |
+0.82% | 93.19B | |
0.00% | 39.62B | |
-10.35% | 33.78B | |
+65.08% | 26.82B | |
-16.15% | 15.35B | |
-6.98% | 13.13B | |
-11.77% | 11.6B | |
-49.19% | 10.26B | |
+3.75% | 9.43B |
- Stock Market
- Equities
- CDMO Stock
- News Avid Bioservices, Inc.
- Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024